Diseases & Longevity · File 09

COPD. Top 3 global cause of death, top 1 in years lived with disability.

Chronic obstructive pulmonary disease affects over 392 million people worldwide (Adeloye 2022 Lancet Respir Med). It is top 3 global cause of death and top contributor to years lived with disability. Its real mortality, however, is mostly cardiovascular and systemic — not strictly respiratory. That reading changes the clinical conversation.

Why COPD is a systemic disease, not just pulmonary

COPD was classically described as airflow obstruction — but the evidence of the last two decades has reconceptualized it as a systemic inflammatory disease. Patients with moderate-severe COPD show elevation of pro-inflammatory cytokines (IL-6, TNF-α, hsCRP), endothelial dysfunction, anemia of chronic disease, secondary sarcopenia, and depression more frequently. Cardiovascular mortality exceeds respiratory mortality in moderate COPD (GOLD II).

GOLD 2023 explicitly incorporates the systemic dimension: it classifies A-B-E groups not only by pulmonary function (FEV1) but by symptoms and exacerbations, and includes in its algorithm the evaluation of cardiovascular and metabolic comorbidities. That makes COPD a natural target for longevity medicine, where management of systemic inflammaging, body composition, and cardiovascular trajectory is already part of the protocol.

The patient with moderate COPD does not die from lack of air — they die from their heart and lost muscle mass. That is where longevity operates.
Adeloye · Lancet Respir Med · 2022

The global weight, in numbers

Quantitative COPD data come from GBD (Global Burden of Disease), GOLD, and recent meta-analyses — including Hu 2024 (CHARLS China, n=13,620) analysis that quantified QALE impact.

  • People with COPD worldwide (2019)

    392M

    Adeloye 2022 Lancet Respiratory Medicine — COPD remains underdiagnosed in LATAM and sub-Saharan Africa, where actual prevalence may be higher.
    — Adeloye et al., Lancet Respir Med 2022

  • Global cause of death (2019)

    Top 3

    After ischemic heart disease and stroke — COPD remains top 3 globally, and top contributor to years lived with disability (YLD) in those over 50.
    — WHO GHE 2020 / GBD 2019

  • Estimated QALE loss associated with COPD (years)

    −4.7

    Hu 2024 CHARLS cohort (n=13,620 Chinese adults) — COPD is associated with one of the largest quality-adjusted life expectancy reductions among the chronic diseases studied.
    — Hu et al., CHARLS 2024

  • Cardiovascular risk increase in COPD

    0.5–4×

    COPD doubles to quadruples MI, HF, and arrhythmia risk — and approximately 30-50% of moderate COPD mortality is cardiovascular, not respiratory.
    — Chen et al., Lancet Respir Med 2015

Chap. 03 · QALE years lost (CHARLS)

Impact on quality of life and functional trajectory

COPD impact on quality of life is among the largest documented across chronic diseases — and it is bidirectional: fatigue reduces activity, inactivity accelerates deconditioning, and deconditioning amplifies dyspnea.

  • Consistent SF-36 PCS reduction

    Eriksen Lancet Healthy Longev 2025

    Patients with moderate-severe COPD show SF-36 physical component reductions comparable to or greater than advanced ischemic heart disease and severe osteoarthritis.

  • Secondary sarcopenia and pulmonary cachexia

    Schols Eur Respir J 2014

    Up to 30% of moderate-severe COPD patients develop secondary sarcopenia or pulmonary cachexia — independent predictor of mortality stronger than FEV1.

  • Depression and anxiety of high prevalence

    Yohannes Chest 2019

    Depression prevalence in moderate-severe COPD is 2-3 times the general population, and anxiety reaches 40%. Both are independent predictors of exacerbations and hospitalization.

  • Exacerbations as inflection point

    Suissa Thorax 2012

    Each severe exacerbation (hospitalization) accelerates FEV1 decline, sustainably worsens SF-36, and increases 1-year mortality risk by approximately 23%. Preventing them is preventing trajectory.

Why a longevity protocol addresses COPD

COPD is a paradigmatic case of fracture between specialties. The pulmonologist manages pulmonary function and exacerbations; the cardiologist, cardiovascular comorbidities; the endocrinologist, associated diabetes; the geriatrician, sarcopenia and frailty; the psychiatrist, depression. Nobody integrates the shared biological axes — and that is why the patient with moderate COPD ends up with five prescriptions and no trajectory view.

A longevity protocol does not replace the pulmonologist. What it does is what the fragmented model does not do well: measure systemic inflammaging, evaluate body composition and strength, optimize cardiovascular profile, address mental health seriously, and design an integrated intervention plan under individual medical judgment. In COPD, that integration is not luxury — it is the real determinant of mortality.

Mortality in moderate COPD is mostly cardiovascular and sarcopenic. Ignoring those axes is ignoring half of the patient's risk.
How we measure it

How it is evaluated at Wellness Care

Three complementary layers under a longevity medicine protocol — none replaces pulmonology management when clinically indicated.

Advanced biomarkers

21 specialized panels across 8 clinical categories — biological age, inflammaging, metabolic profile, functional hormonal, microbiota. The quantitative layer.

Explore →

Functional medicine

Shared root causes — mitochondrial dysfunction, inflammaging, neuroendocrine dysregulation — before organ pathology.

Explore →

Bioregulatory medicine

Autonomic regulation, HRV, stress response. The functional trajectory that precedes clinical diagnosis.

Explore →

The Longevity Program

How this assessment integrates into the full program — from initial valuation to individualized protocol design under medical judgment.

Explore →
Featured evidence

Key evidence supporting this approach

Four publications framing COPD in the longevity conversation — global burden, GOLD guideline, systemic inflammaging evidence, and cardiovascular comorbidity.

«La EPOC afectó a 392 millones de personas en el mundo en 2019 — un aumento de 85% respecto a 1990, con concentración creciente en países de ingresos medios y subdiagnóstico persistente en regiones de menor ingreso.»

Carga global y prevalencia 2019
Adeloye et al., Lancet Respir Med 2022
Carga global y prevalencia 2019

«El abordaje moderno de EPOC requiere la evaluación e intervención sobre comorbilidades cardiovasculares, metabólicas y de salud mental — son parte integral del pronóstico, no un anexo.»

Estándar internacional de manejo EPOC
GOLD 2023 Report
Estándar internacional de manejo EPOC

«EPOC se asocia con una de las mayores reducciones de expectativa de vida ajustada por calidad entre las enfermedades crónicas estudiadas — el efecto persiste tras ajuste por comorbilidades múltiples.»

Cohorte china QALE n=13,620
Hu et al., CHARLS 2024
Cohorte china QALE n=13,620

Frequently asked questions about COPD

The most recurrent questions about COPD, its systemic nature, and why longevity medicine complements pulmonology in cardiovascular mortality and associated sarcopenia.

01

Do only smokers develop COPD?

No. Smoking remains the most frequent cause, but 20-30% of COPD patients never smoked.

Other factors:

· Biomass smoke (wood, coal)
· Chronic environmental pollution
· Occupational exposure (dust, gases, vapors)
· Alpha-1 antitrypsin deficiency
· Severe childhood respiratory infections
· Poorly controlled asthma
· Low birth weight

In LATAM, indoor biomass smoke in rural areas is a frequently underestimated cause.

02

How is COPD diagnosed?

Diagnosis requires post-bronchodilator spirometry:

· FEV1/FVC < 0.70 post-bronchodilator → confirms airflow obstruction

Severity is classified by FEV1 (% predicted) in GOLD 1-4.

Modern approach (GOLD 2023) also classifies by:

· Symptoms — CAT, mMRC
· Exacerbations — A-B-E groups

Diagnosis additionally requires an exposure context (smoking, biomass, occupational) and exclusion of other causes.

03

Why is COPD considered a systemic disease?

Because chronic pulmonary inflammation is associated with elevation of systemic markers:

· IL-6, TNF-α, hsCRP, fibrinogen

These affect endothelium, muscle, bone, nervous system, and hypothalamic-pituitary axis.

That explains why patients with moderate COPD have:

· Higher cardiovascular risk
· Secondary sarcopenia
· Osteoporosis
· Anemia of chronic disease
· Depression
· Cognitive decline

Even when FEV1 is only moderately reduced. Real mortality is systemic, not pulmonary.

04

What interventions change COPD trajectory?

Interventions with demonstrated mortality effect:

· Exposure cessation (tobacco, biomass) — the most important
· Pulmonary rehabilitation (exercise + education + nutrition)
· Long-acting bronchodilators and inhaled corticosteroids per phenotype
· Home oxygen therapy in chronic hypoxemia
· Lung volume reduction surgery in selected cases
· Vaccination — influenza, pneumococcus, COVID-19, RSV

Cardiovascular comorbidity management and sarcopenia prevention are additional prognostic determinants.

05

What role does exercise play in COPD?

Central.

Pulmonary rehabilitation — combining aerobic exercise, strength training, and education — is one of the best-evidence interventions in moderate-severe COPD.

Benefits:

· Improves functional capacity
· Reduces dyspnea
· Improves quality of life
· Reduces hospitalizations for exacerbation

Strength training is especially relevant due to secondary sarcopenia.

The idea that the COPD patient "should not exert" is contrary to evidence — deconditioning worsens everything.

06

When should I consult for suspected COPD?

A spirometry is worthwhile if you are 40+ and have:

History:

· Smoking (even past)
· Biomass smoke exposure
· Occupational exposure

Symptoms:

· Progressive dyspnea
· Chronic cough with morning expectoration
· Recurrent wheezing
· Frequent respiratory infections

COPD is one of the most underutilized diagnoses in LATAM: many patients are labeled as "bronchitic" or "asthmatic" without functional confirmation.

The conversation that's missing

COPD is the disease where the fracture between specialties is most visible — and where an integrated, trajectory-based approach is most urgent.

Measure systemic inflammaging, evaluate body composition and strength, optimize cardiovascular profile, address mental health seriously, and coordinate with pulmonology — that is what a longevity clinic does in COPD.

Breathless or diagnosed COPD?

Book a comprehensive respiratory and longevity assessment

We evaluate clinical history, systemic inflammatory profile (inflammaging), body composition and strength, cardiovascular biomarkers (mortality in moderate COPD is mostly cardiovascular), and quality of life. The assessment does not replace the pulmonologist — it complements them.

Book respiratory assessment